Recurrent Respiratory Tract Infections Clinical Trial
Official title:
Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric
Up to date, some clinical trial have evaluated the efficacy and safety of Vitamin D
supplementation in children with RRI, with no conclusive information.
Therefore, the investigators designed a prospective, single-blind, clinical trial to evaluate
whether oral supplementation with vitamin D from October to April reduces the global health
burden of recurrent respiratory tract infections in a primary care setting.
The primary outcome was evaluated if Vitamin D supplementation during autumn and winter can
reduce the number of respiratory tract infections in children diagnosed with recurrent
respiratory tract infections the seasons before.
Secondary objectives was the assessment of Vitamin D supplementation benefits on global
socioeconomic burden of recurrent respiratory tract infections in a primary care setting,
according to number of visits to the primary care paediatrician and use of antibiotics due to
respiratory tract infections.
The University study personnel randomly allocated patients to receive, from October to March,
a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) or
not.
Randomization was performed using a free web-based service that offers random assignment;
patients were randomized considering gender and age class (up to 12 months; beyond 1 years).
The primary care practitioner was blinded regarding the study group allocation.
Inclusion criteria were: a) patients diagnosed the seasons before with: ≥ 6 respiratory
infections per annum OR ≥ 1 respiratory infections per month involving the upper airways from
September to April OR ≥ 3 respiratory infections per annum involving the lower airways. b)
patients with no findings suggestive of an immunodeficiency on history and physical
examination.
From the recruitment, parents recorded number and type of diagnosed respiratory tract
infections, number of ambulatory visits, use of antibiotics and duration of symptoms in a
structured diary.
Upper Respiratory Tract Infections (URTIs) comprehends diagnosis of acute otitis media, acute
rhinosinusitis and acute pharyngotonsillitis. Lower Respiratory Tract Infections (LRTIs)
comprehend diagnosis of bronchiolitis and pneumonia.
All parents had a close telephone contact to help them in the diary compilation. Adverse
events related to the protocol were monitored. Missing data were recovered through the
information system of the primary care practitioner.
Quantitative data were expressed as mean and standard deviation. To compare the mean between
the two groups, Student's t-test for unpaired was used. The frequency of each visits to the
pediatricians and use of antibiotics in the two group was calculated and expressed as a
percentage. The χ² test was used to compare the percentages between the two groups. For all
tests, P-values <0.05 were considered significant.
Since Italian National Health System covers all costs for pediatrician visits and
antibiotics, cost assessment was made analysing the costs regarding the frequency of each
parameters in treated and nontreated group. We considered as direct cost National Health
System: Medical examination (20,66 euros for each examination, as provided by the Italian
Ministry of Health) and use of Antibiotics (the cost was as in the list of the National Drug
Authority).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05053776 -
Clinical and Laboratory Predictors of Respiratory Morbidities in CP Children
|
||
Terminated |
NCT04408443 -
Evaluation of Lactobacillus Reuteri DSM 17938 + Vitamin D3 in the Prevention of RRI in Paediatric Patients
|
N/A | |
Recruiting |
NCT05684848 -
Evaluate the Effect of Nasal Spray in the Prevention of RTI in Children With Pre-school Wheezing
|
N/A | |
Recruiting |
NCT06201494 -
Prospective Multicentre Study on Symptoms in First-onset Bronchial Asthma in Children and Adolescents
|
||
Completed |
NCT04322669 -
Study of Pidotimod in Children With Recurrent Respiratory Tract Infections (RRI)
|
Phase 4 |